Are GLP-1 weight loss drugs actually worth the cost? What a new ACP systematic review found

The question we hear most often in new-patient weight loss visits is not "which drug works best." It is "can I actually afford this, and is it worth it?" That is a reasonable question, and until recently the honest answer was: we have great efficacy data and almost no rigorous cost-effectiveness data. That changed in 2025.

The American College of Physicians published a systematic review specifically examining the cost-effectiveness of pharmacologic treatments for overweight and obesity in adults -- the first major society-level analysis to put economics alongside outcomes in a single evidence synthesis (https://pubmed.ncbi.nlm.nih.gov/42296505/). We have been reading it carefully. What follows is what the data actually say, what they do not say, and what they mean if you are weighing a GLP-1 prescription against your monthly budget.

What the ACP review actually looked at

The review analyzed cost-effectiveness studies across the major FDA-approved weight loss medications, including orlistat (Xenical, Alli), phentermine-topiramate extended-release (Qsymia), naltrexone-bupropion (Contrave), liraglutide 3 mg (Saxenda), semaglutide 2.4 mg (Wegovy), and tirzepatide (Zepbound). It ran alongside a companion network meta-analysis of benefits and harms from the same ACP working group (https://pubmed.ncbi.nlm.nih.gov/42296503/), so efficacy and cost data were evaluated in parallel rather than in separate silos.

Cost-effectiveness in these studies is most often expressed as cost per quality-adjusted life year (QALY) -- a standard health economics unit that blends both length and quality of life into a single number. The threshold most US analyses use is somewhere between $50,000 and $150,000 per QALY. Below that range, a treatment is generally considered worthwhile from a societal standpoint. Above it, the value argument becomes harder to sustain.

The review found that GLP-1 receptor agonists -- semaglutide and tirzepatide chief among them -- show favorable cost-effectiveness ratios when their downstream benefits are included in the model. Those downstream benefits include reduced risk of major cardiovascular events, delayed progression to type 2 diabetes, reduced rates of sleep apnea complications, and fewer orthopedic procedures related to excess weight. When those avoided costs are credited back, the high monthly price tag for GLP-1 medications starts to look different.

Why sticker price and cost-effectiveness are not the same thing

This distinction matters, and it is one that insurance coverage decisions often get wrong. Older weight loss agents -- phentermine-topiramate in particular -- cost a fraction of what Wegovy or Zepbound costs per month. If you are comparing drug costs alone, the older agents win easily.

But weight loss medications are not single-period purchases. They are long-term interventions with long-term consequences. A drug that costs $1,400 per month and prevents a $60,000 hospitalization for a heart attack, a $35,000 bariatric surgery, or a decade of diabetes management looks very different over a 10-year horizon than it does on a one-month pharmacy statement.

Semaglutide, specifically, has SELECT trial data showing a 20% reduction in major adverse cardiovascular events in people with obesity and established cardiovascular disease -- without diabetes as a requirement (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563). That is a hard outcome, not a surrogate marker. When a drug reduces heart attacks, the cost-effectiveness math shifts in its favor significantly.

Tirzepatide is newer and its cardiovascular outcome trial (SURMOUNT-MMO) results are still maturing, but the weight loss magnitude in SURMOUNT-1 was 20.9% of body weight at 72 weeks on the 15 mg dose (https://www.nejm.org/doi/full/10.1056/NEJMoa2206038). Greater weight loss means more downstream risk reduction, which likely means a cost-effectiveness profile at least as strong as semaglutide's over time.

Where the older medications still make a strong argument

We want to be honest here, because the GLP-1 conversation can crowd out reasonable alternatives.

Phentermine-topiramate extended-release produces clinically meaningful weight loss -- roughly 8 to 10% of body weight in trials -- at a monthly cost that is dramatically lower than GLP-1 agents. For someone without cardiovascular disease or diabetes who tolerates the medication well, this is a legitimate first-line option that the ACP review supports. The side-effect profile is different (cognitive effects, paresthesias, teratogenicity), and it is not right for most patients, but it earns its place in the conversation.

Naltrexone-bupropion (Contrave) shows more modest weight loss (roughly 5% over placebo) and carries a cardiovascular warning that limits use in certain populations. Its cost-effectiveness is less favorable by most models.

Orlistat, the lipase inhibitor, has the longest safety record of any weight loss drug on the market. It is also the least effective by weight-loss magnitude. It remains a reasonable adjunct for select patients, particularly those managing lipid-heavy diets, but its cost-effectiveness as a primary agent is modest.

The right medication is not always the newest one. It is the one that fits your biology, your risk profile, your comorbidities, and yes -- your real-world budget and access situation. That is a conversation we have in full at your intake visit.

What the data say about staying on these medications

Here is the part of the cost-effectiveness story that does not always make the headlines. Almost every pharmacoeconomic model for GLP-1 medications shows cost-effectiveness that improves the longer the patient stays on the drug -- because weight regain after stopping erases both the health benefits and the downstream cost savings.

The STEP 1 extension trial showed that participants who stopped semaglutide regained about two-thirds of their lost weight within one year (https://pubmed.ncbi.nlm.nih.gov/36216945/). That is not a failure of willpower. It is the biology of a chronic disease. Obesity involves persistent neuroendocrine dysregulation -- appetite hormones, satiety signaling, metabolic rate adaptation -- that do not normalize permanently after weight loss. GLP-1 medications work in part by correcting those signals, and when you stop the medication, the signals shift back.

For the cost-effectiveness calculation, this means treating obesity pharmacologically as you would treat hypertension: as a long-term intervention, not a short course. If you are planning to take semaglutide for three months and stop, the cost-benefit ratio is much weaker than if you are planning a sustained protocol with regular monitoring. We build our medical weight loss plans around this reality.

For more detail on how we approach dosing, titration, and plateau management in practice, see our post on how to break a GLP-1 weight loss plateau and our semaglutide vs. tirzepatide comparison.

The compounded GLP-1 question -- and why we do not go there

We get asked about compounded semaglutide and tirzepatide regularly, and we understand why. A compounded version of these medications costs a fraction of the branded price, and during periods of shortage, compounding pharmacies filled a genuine gap in access.

The FDA has now issued safety communications specifically about compounded semaglutide and tirzepatide products, citing reports of dosing errors, contamination risks, and the use of salt forms (semaglutide sodium and acetate) that differ from the tested, approved molecular form (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss). The branded shortages that legally permitted compounding have been resolved for both Wegovy and Zepbound.

A cost-effectiveness analysis that starts with a cheaper, unverified drug is not a cost-effectiveness analysis -- it is a cost analysis with unstated safety assumptions. At NoMi Beach Health, we prescribe only FDA-approved, commercially manufactured agents. We will tell you what they cost, help you navigate prior authorization where it applies, and be direct about what is and is not covered.

What this means for how we build your plan

The ACP review does not tell us which medication to prescribe for any individual. What it tells us is that the economic case for evidence-based pharmacologic treatment of obesity is real and defensible, particularly for agents with outcome data beyond weight loss alone.

When we see you for a medical weight loss evaluation, we are looking at several things together: your current weight and BMI, your metabolic panel and fasting glucose, your cardiovascular risk factors, your medication history and tolerability, your insurance situation, and your personal goals. We read the cost-effectiveness literature not to justify a preferred drug, but to give you an honest picture of value -- including the scenarios where an older, cheaper agent may be the right call.

Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) built NBH's weight loss program around this kind of evidence-anchored thinking. We are not a GLP-1 clinic. We are a concierge practice that uses GLP-1 medications when they are the right tool -- and explains clearly when they are not.

For a broader overview of how we approach the GLP-1 landscape in 2026, including dosing ranges, patient selection, and what to expect at each stage, see our GLP-1 weight loss concierge guide.

The bottom line

The new ACP systematic review gives clinicians and patients something valuable: a rigorous, society-level framework for thinking about weight loss medication value, not just efficacy. The short version is this -- GLP-1 medications are expensive upfront and cost-effective over time when their cardiovascular and metabolic benefits are credited. Older agents are cheaper upfront and may be entirely appropriate depending on your situation. Compounded versions are neither regulated nor recommended. And stopping any of these medications early tends to erase both the weight loss and the economic rationale for having started.

If you are ready to have this conversation with a clinician who will look at your actual numbers and give you a real answer -- not a protocol built for a population average -- our medical weight loss program is the place to start. Book a new-patient visit at nomibeach.health or call us at (786) 744-5152. We will review your labs, talk through your options with full transparency on cost, and build a plan you can actually sustain.